Week 10: Minor Cannabinoids: CBN, CBG, and Beyond

Beyond THC and CBD

THC and CBD dominate most cannabis conversations, but they represent just two of over 100 cannabinoids in the cannabis plant. The minor cannabinoids — compounds present in smaller quantities — are increasingly capturing attention. As extraction technology advances, products featuring CBN, CBG, CBC, and others have become more accessible. The term "minor" refers to quantity, not importance.

CBN — Cannabinol

CBN is one of the most recognized minor cannabinoids, frequently discussed in the context of evening routines. Unlike most cannabinoids, CBN forms as a degradation product of THC — when THC ages and is exposed to heat and oxygen, it gradually converts to CBN. This is why older cannabis has higher CBN levels. CBN is generally mildly psychoactive, though much less so than THC. It has become popular in nighttime products, often combined with CBD. CBN products tend to cost more due to additional processing required.

CBG — Cannabigerol

CBG is sometimes called the "mother cannabinoid" because CBGA, its acidic form, serves as the precursor from which THCA, CBDA, and CBCA are synthesized. CBG is essentially the building block for other major cannabinoids. Because it converts to other cannabinoids as the plant matures, most harvested cannabis contains very little CBG, typically less than one percent. To meet demand, breeders have developed high-CBG hemp cultivars harvested earlier in the growth cycle. CBG is non-intoxicating and interacts with both CB1 and CB2 receptors in its own distinct way.

CBC — Cannabichromene

CBC is actually one of the more abundant cannabinoids the plant produces but receives far less attention. It is non-intoxicating and does not bind strongly to CB1 or CB2 receptors but may interact with other receptor systems including TRPV1 and TRPA1. Fewer CBC-specific products exist currently, though this is changing as interest grows.

Other Emerging Cannabinoids

THCV is a THC analog sometimes described as producing shorter, clearer effects. CBDV is a CBD variant with its own characteristics. Delta-8 THC has become controversial due to synthetic conversion questions. THCA and CBDA, the acidic precursors in raw cannabis, are gaining interest as distinct compounds rather than simply pre-decarboxylated forms of familiar cannabinoids.

The Entourage Effect

The concept of the entourage effect is particularly relevant when discussing minor cannabinoids. Minor cannabinoids are central to the entourage effect — the concept that cannabis compounds work synergistically, with the combined result differing from what any single compound produces alone. Full-spectrum products retain the natural variety, potentially allowing minor cannabinoids to contribute to the overall experience even in small amounts. Isolated minor cannabinoid products offer the opposite approach, allowing you to explore each compound's individual characteristics without interference from other compounds.

Evaluating Minor Cannabinoid Products

Apply the same quality standards as any cannabis product: third-party testing confirming cannabinoid content, transparent sourcing, and clear labeling. Because less is known about minor cannabinoids compared to THC and CBD, approach with realistic expectations and appropriate caution. These products are often pricier due to lower yields and specialized extraction processes. Individual responses vary significantly — what works well for one person may not produce the same experience for another. Healthcare provider consultation is particularly important if you take medications, as interaction data for minor cannabinoids is limited.

This content is for educational purposes only. It does not constitute medical advice. Cannabinoid products are not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before making decisions based on this information.